Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937968 | 0.92 | ALDH1A1 (0.47) | PTGS2ALDH1A1HSD17B10HPGDBCL2L1 | |
| SCHEMBL60313 | 0.92 | ALDH1A1 (0.48) | PTGS2ALDH1A1HSD17B10HPGDBCL2L1 | |
| SCHEMBL11898487 | 0.86 | ALDH1A1 (0.42) | PTGS2ALDH1A1HSD17B10HPGDBCL2L1 | |
| SCHEMBL10988620 | 0.77 | PTGS2 (0.52) | PTGS2ALDH1A1HSD17B10HPGDCYP2A6 | |
| SCHEMBL7182219 | 0.77 | MEN1 (0.44) | PTGS2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL28317839 | 0.77 | PTGS2 (0.52) | PTGS2ALDH1A1BCL2L1SMN1; SMN2CASP3 | |
| SCHEMBL314438 | 0.77 | CYP3A4 (0.50) | ALDH1A1HSD17B10HPGDMAPK1TDP1 | |
| Tannin Pyrogallol SCHEMBL13685561 | 0.76 | ALDH1A1 (0.64) | PTGS2ALDH1A1HSD17B10HPGDBCL2L1 | |
| SCHEMBL30257106 | 0.76 | ALDH1A1 (0.64) | PTGS2ALDH1A1HSD17B10HPGDBCL2L1 | |
| SCHEMBL6754212 | 0.76 | ALDH1A1 (0.55) | PTGS2ALDH1A1HSD17B10HPGDBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024128000-A1 | ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE | 東京応化工業株式会社 | 2024-06-20 | — | — | WO | disclosed |
| CN-114728170-B | Compounds active on nuclear receptors | 纽韦卢森公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023205251-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2023-10-26 | — | — | WO | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023169096-A1 | POSITIVE ELECTRODE ACTIVE MATERIAL, SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRIC DEVICE | 宁德时代新能源科技股份有限公司 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172187-A1 | GLOBULAR NANOSTRUCTURES HAVING AN ANCHORING LAYER | SPAGO NANOMEDICAL AB (SE) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172186-A1 | NANOSTRUCTURES AND APPLICATIONS THEREOF | SPAGO NANOMEDICAL AB (SE) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172185-A1 | COMPOUNDS FOR COATING OF NANOSTRUCTURES | SPAGO NANOMEDICAL AB (SE) | 2023-09-14 | — | — | WO | disclosed |
| EP-1541570-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE | MERCIAN CORPORATION (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1522540-A1 | AZAARENE DERIVATIVES | Eisai Co., Ltd. (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-20040229889-A1 | HDAC inhibitor | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| WO-2004063169-A1 | HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-20040138271-A1 | Benzene compound and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375472-A1 | BENZENE COMPOUND AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | PTGS2 2841/4885ALDH1A1 2068/4885HSD17B10 1048/4885 |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | PTGS2 4606/4885ALDH1A1 112/4885HSD17B10 499/4885 |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | PTGS2 4248/4885ALDH1A1 3655/4885HSD17B10 1032/4885 |
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | PTGS2 1271/4885ALDH1A1 1638/4885HSD17B10 499/4885 |
| US-20040229889-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | PTGS2 2990/4885ALDH1A1 401/4885HSD17B10 235/4885 |
| US-20040138271-A1 | Benzene compound and salt thereof | INSR, SLC5A1, IRS1 | PTGS2 4516/4885ALDH1A1 1736/4885HSD17B10 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.